伊布替尼对SARS-CoV-2引起的呼吸道并发症是否有作用？一名慢性淋巴细胞白血病患者的临床经验。
May Ibrutinib Have Activity in Respiratory Complications by SARS-CoV-2? Clinical Experience in a Patient with Chronic Lymphocytic Leukemia.
作者信息
Molina-Cerrillo Javier, Marquet-Palomanes Juan, Alonso-Gordoa Teresa, López-Jiménez Javier, Grande Enrique
机构信息
Medical Oncology Department, University Hospital Ramon y Cajal, 28034 Madrid, Spain.
The Ramón y Cajal Health Research Institute (IRYCIS), CIBERONC, 28034 Madrid, Spain.
出版信息
Healthcare (Basel). 2021 Jan 15;9(1):78. doi: 10.3390/healthcare9010078.
COVID-19 is affecting many countries all around the world. Unfortunately, no treatment has already been approved for the management of patients infected by SARS-CoV-2. It seems that SARS-CoV-2 can induce the activation of an exaggerated immune response against itself according to different mechanisms that are not really well known. Inflammatory interleukins, such as IL-6 among others, play a central role in this uncontrolled immune response. There is a strong rational under ibrutinib use in in the treatment of immune-based diseases, such a as GVHD or RA. Ibrutinib achieves a reduction in the production of TNFα, IL1, IL-6 and Monocyte chemo-attractant protein-1 (MCP-1) by neutrophils and macrophages, that are key players in keeping the inflammatory process. We present our clinical experience about ibrutinib use in ARDS secondary to SARS-CoV-2 in a patient with chronic lymphocytic leukemia (CLL).
新型冠状病毒肺炎正在影响全球许多国家。不幸的是，目前尚无已获批用于治疗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者的疗法。似乎SARS-CoV-2可根据一些尚未完全明确的不同机制，诱导针对自身的过度免疫反应激活。诸如白细胞介素-6（IL-6）等炎性白细胞介素在这种失控的免疫反应中起核心作用。依鲁替尼用于治疗诸如移植物抗宿主病（GVHD）或类风湿性关节炎（RA）等基于免疫的疾病，存在充分的理论依据。依鲁替尼可使中性粒细胞和巨噬细胞产生的肿瘤坏死因子α（TNFα）、白细胞介素-1（IL1）、白细胞介素-6和单核细胞趋化蛋白-1（MCP-1）减少，而这些细胞是维持炎症过程的关键因素。我们介绍了一名慢性淋巴细胞白血病（CLL）患者使用依鲁替尼治疗SARS-CoV-2继发急性呼吸窘迫综合征（ARDS）的临床经验。
Zotero 插件